Long-Term Effects for Bone Marrow Transplant

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: Stanford University

Disqualifiers: Relapsed malignancy, Consent issues

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-12 weeks

800 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand the long-term effects of stem cell transplants in children. Researchers seek to gather data to improve treatment plans and anticipate future health issues for children who have undergone these transplants. This study suits children who have received a hematopoietic stem cell transplant (a procedure that replaces damaged blood-forming cells) and are currently in follow-up care. As a Phase 4 trial, this research explores how the already FDA-approved treatment benefits more patients, providing valuable insights for future care.

Why are researchers excited about this trial?

Researchers are excited about hematopoietic stem cell transplantation (HSCT) because it offers a unique approach for treating various blood and immune disorders. Unlike traditional treatments like chemotherapy and immunosuppressive drugs, HSCT introduces healthy stem cells that can regenerate the patient's blood and immune systems, potentially providing a long-term cure rather than just symptom management. This treatment is particularly promising because it can replace diseased cells at their source, offering hope for patients with conditions that currently have limited options.

Who Is on the Research Team?

Ami Shah

Principal Investigator

Stanford University

Are You a Good Fit for This Trial?

Inclusion Criteria

Participant is scheduled to receive OR has received a hematopoietic stem cell transplant (HSCT) for any condition.

Participant may have had a HSCT in another institution than Lucile Packard Children's Hospital (LPCH) yet has transferred follow-up long-term care to our institution and is being seen through the late-effects clinic from the Pediatric HSCT program.

Participant AND/OR parent/legally authorized representative is able to provide written informed consent and assent (as applicable) for participation.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo hematopoietic stem cell transplantation and initial recovery

8-12 weeks

Follow-up

Participants are monitored for long-term effects and late complications post-transplant

Lifetime

Periodic visits for physical examination, laboratory, and medical tests

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+